07:45 AM EST, 03/03/2025 (MT Newswires) -- Boston Scientific ( BSX ) said Monday it agreed to acquire medical device company SoniVie.

Boston Scientific ( BSX ) currently owns an equity stake of around 10 percent in SoniVie. The transaction consists of an upfront payment of $360 million for the remaining 90% stake and up to $180 million upon achievement of a regulatory milestone.

SoniVie's main product is the Tivus intravascular ultrasound system, an investigational technology designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation for hypertension. The Tivus system is designed to help reduce activity in the kidney's renal nerves and serve as an alternative or adjunctive therapy to medications to help regulate blood pressure.